Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

262 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial.
Livingstone E, Zimmer L, Hassel JC, Fluck M, Eigentler TK, Loquai C, Haferkamp S, Gutzmer R, Meier F, Mohr P, Hauschild A, Schilling B, Menzer C, Kiecker F, Dippel E, Roesch A, Ziemer M, Conrad B, Körner S, Windemuth-Kieselbach C, Schwarz L, Garbe C, Becker JC, Schadendorf D; Dermatologic Cooperative Oncology Group. Livingstone E, et al. Among authors: hassel jc. Lancet. 2022 Oct 1;400(10358):1117-1129. doi: 10.1016/S0140-6736(22)01654-3. Epub 2022 Sep 10. Lancet. 2022. PMID: 36099927 Clinical Trial.
Checkpoint inhibitor-induced bullous pemphigoid differs from spontaneous bullous pemphigoid.
Kramer N, Müller G, Zierold S, Röckel M, Fröhlich W, Schefzyk M, Kumbrink J, Hassel JC, Berking C, Ziemer M, Nashan D, French LE, Vera J, Kerl-French KE, Gutzmer R, Heinzerling L. Kramer N, et al. Among authors: hassel jc. J Eur Acad Dermatol Venereol. 2024 Feb 24. doi: 10.1111/jdv.19860. Online ahead of print. J Eur Acad Dermatol Venereol. 2024. PMID: 38400651 No abstract available.
First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: 4-year follow-up from part B of the JAVELIN Merkel 200 study.
D'Angelo SP, Lebbé C, Mortier L, Brohl AS, Fazio N, Grob JJ, Prinzi N, Hanna GJ, Hassel JC, Kiecker F, von Heydebreck A, Güzel G, Nghiem P. D'Angelo SP, et al. Among authors: hassel jc. ESMO Open. 2024 May 13;9(5):103461. doi: 10.1016/j.esmoop.2024.103461. Online ahead of print. ESMO Open. 2024. PMID: 38744102 Free PMC article.
Preferences of physicians for treatment-related toxicity vs. recurrence in melanoma (GERMELATOX-A): the doctors' perspective.
Kähler KC, Gutzmer R, Angela Y, Livingstone E, Lodde G, Meiss F, Rafei-Shamsabadi DA, Weyer-Fahlbusch SS, Nashan D, Loquai C, Hassel JC, Sachse MMM, Maul LV, Heinzerling L, Heppt MV, Colapietro C, Rusch J, Blome C. Kähler KC, et al. Among authors: hassel jc. J Cancer Res Clin Oncol. 2024 May 14;150(5):252. doi: 10.1007/s00432-024-05713-6. J Cancer Res Clin Oncol. 2024. PMID: 38743104 Free PMC article.
An Online Decision Aid for Patients With Metastatic Melanoma—Results of the Randomized Controlled Trial "PEF-Immun".
Grabbe P, Borchers MS, Gschwendtner KM, Strobel S, Wild B, Kirchner M, Kälber K, Rendon A, Steininger J, Meier F, Hassel JC, Bieber C. Grabbe P, et al. Among authors: hassel jc. Dtsch Arztebl Int. 2024 Jun 14;(Forthcoming):arztebl.m2024.053. doi: 10.3238/arztebl.m2024.053. Online ahead of print. Dtsch Arztebl Int. 2024. PMID: 38566437 Clinical Trial.
262 results